Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Isolation and characterization of nanocrystalline cellulose from cocoa pod husk (CPH) biomass wastes
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Adjunct/Symptom Burden Support Therapies that do not directly target mast cells but may reduce overall inflammatory or neurologic burden
The presence of benzyl alcohol allows the solution to remain bacteriostatic, supporting repeated vial access when proper aseptic techniques are consistently followed
